Gene Editing Tools & Services

A Faster Path to the Right Edit.

Five editing modalities. AI-driven discovery. One integrated platform.

Generating clear answers on gene editing feasibility can take years of internal effort and significant capital before programs have the data they need to move forward. ElevateBio provides a faster, cleaner path.

We start with your biology: matching the right editing strategy to your target, then selecting the best enzyme from our proprietary portfolio of validated editors. Our scientific team engineers promising candidates for potency, specificity, and safety. When no existing enzyme fits, we mine a catalog of over 10 billion protein sequences or apply generative AI to engineer novel candidates for your target.

Three Steps. One Integrated Engine.

1 Match the Modality

Disease biology and therapeutic goals guide selection of the editing approach. Whether correcting a point mutation, replacing a gene, or modulating expression without touching the DNA sequence, the right type of edit is identified first.

2 Find the Optimal Enzyme

We draw first from a broad portfolio of characterized enzymes, then apply our AI engine to identify novel candidates if existing systems fall short, ensuring diverse PAM recognition and delivery requirements are met.

3 Engineer for Precision

Our scientific team applies deep protein engineering expertise, an established directed evolution platform, and machine learning tools to optimize candidates across potency, specificity, and off-target safety.

<6 months
to feasibility data and go/no-go decision*

10B+
proteins catalogued for AI-driven discovery

3x
faster to lead identification than traditional methods

Centralized ownership & streamlined licensing
provides a straightforward path to accessing our technology.

Five Modalities. Broad Disease Coverage.

Epigenetic Editing

Tune gene expression up or down without altering DNA sequence. When delivered with LNPs, reversible and re-dosable, well suited to diseases where permanent edits are not ideal.

Targeted Gene Insertion

Delivers large functional sequences to defined genomic sites for durable, consistent expression. Well suited for full gene replacement and programs requiring predictable transgene expression.



Base Editing

Single-nucleotide correction without strand breaks. Engineered deaminases broaden addressable variants and sharpen editing window precision.

Reverse Transcriptase Editing

All 12 base conversions plus small insertions and rewrites. No double-strand breaks, no donor template required. Expands reach beyond base editing.

Nuclease-based Editing

Durable gene knock-out. Proprietary nucleases with diverse PAM coverage for broad genomic access.

Bring Us a Target. Get the Data to Decide.

Internal gene editing programs move slowly. Building the expertise and breadth to evaluate multiple modalities across multiple targets requires significant time and investment before programs have the data they need. ElevateBio is built to change that equation.

We work as an extension of your team, with full visibility throughout, to deliver high-quality data packages on your timeline, using editors engineered specifically for your target.

AI-Driven Discovery & Molecular Engineering

- **10B+ protein catalog:** providing the evolutionary diversity to train AI models across multiple gene editing modalities.
- **Generative AI mines the protein catalog** to design and prioritize novel candidates for experimental validation if existing, characterized enzymes fall short.
- **Our established protein engineering platform**, supported by machine learning and experienced scientists, refines candidates across potency, specificity, bystander profile, and off-target safety.
- **8x more** guide RNA options per target and 4x broader editing window access than traditional methods.
- **Broad PAM** diversity across a proprietary nuclease library, granting access to virtually any genomic region.
- **Comprehensive off-target analysis** combining computational prediction with experimental assays to meet FDA safety requirements.

What Partners Gain

Reduced Risk

- Validate gene editing feasibility before full program investment
- Data-driven go/no-go decisions
- Data packages structured to support regulatory filings

Integrated IP Strategy

- Proprietary enzymes unavailable anywhere else
- Centralized ownership. Streamlined licensing.
- A straightforward path to clinic and commercial development

Speed to Decision

- Proof of concept results in under 6 months*
- Rapid onboarding with predictable timelines
- Integrated path to cGMP manufacturing

Collaborative Excellence

- Full transparency and shared oversight throughout
- ElevateBio scientists work alongside yours
- High-quality data packages to support decisions and filings

Start With a Proof of Concept

Up to 3 gene editors for your target, plus feasibility and initial safety data. **Results in under 6 months.**

Proof of Concept

<6 months. Standard terms. Fixed deliverable. No long-term obligation.*

Clinical Candidate

Optimize toward an IND filing. *In vivo* validation. Typically 18 months or less.

Pipeline Model

Full R&D collaboration across multiple targets. Scope and timeline by agreement.

*Via Proof of Concept engagement. Excludes targeted gene insertion.

Start the Conversation

→ elevate.bio/technologies/gene-editing

partnerships@elevate.bio

ELEVATE.BIO